SCHEMBL15629940

SCHEMBL15629940

CCc1ccc2c(c1)CCCS2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.41
SLC5A2 P31639 2/20 0.39
NPC1 O15118 2/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 2/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
TRPA1 O75762 1/20 0.34
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
SRD5A1 P18405 1/20 0.33
POLB P06746 1/20 0.33
PTGS1 P23219 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14172986 0.89 CTSL (0.46) CTSLSLC5A2ALDH1A1MAPTTRPA1
SCHEMBL16519839 0.84 SLC5A2 (0.42) SLC5A2HTTALDH1A1MAPTPTGS1
SCHEMBL16499627 0.82 SLC5A2 (0.44) CTSLSLC5A2MAPTPTGS1PTGS2
SCHEMBL31726624 0.82 SLC5A2 (0.44) CTSLSLC5A2MAPTPTGS1PTGS2
SCHEMBL9838345 0.77 AKR1B1 (0.48) SLC5A2GAAALDH1A1MAPTTSHR
SCHEMBL11339018 0.76 ALDH1A1 (0.38) CTSLGAAALDH1A1MAPTTSHR
SCHEMBL12108116 0.75 CTSL (0.42) CTSLNPC1RAB9AHTTSMN1; SMN2
SCHEMBL20382503 0.75 SLC5A2 (0.34) SLC5A2PTGS1PTGS2SLC6A4
SCHEMBL442330 0.74 NPC1 (0.53) NPC1RAB9AGAAHTTSMN1; SMN2
SCHEMBL30361595 0.74 NPC1 (0.53) NPC1RAB9AGAAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222047-A1 C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-08-04 US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 CTSL 4497/4885SLC5A2 1/4885NPC1 265/4885
US-20160222047-A1 C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF SLC5A1, SLC5A2, UGGT1 CTSL 1017/4885SLC5A2 2/4885NPC1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.